Singular Genomics Systems (OMIC) Stock Forecast & Price Target

$7.80

-0.59 (-7.03%)

(As of 07/26/2024 ET)

Singular Genomics Systems - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 2 Analyst Ratings

Based on 2 Wall Street analysts who have issued ratings for Singular Genomics Systems in the last 12 months, the stock has a consensus rating of "Hold." Out of the 2 analysts, 2 have given a hold rating for OMIC.

Consensus Price Target

$10.75
37.82% Upside

High Forecast	$15.00
Average Forecast	$10.75
Low Forecast	$6.50

According to the 2 analysts' twelve-month price targets for Singular Genomics Systems, the average price target is $10.75. The highest price target for OMIC is $15.00, while the lowest price target for OMIC is $6.50. The average price target represents a forecasted upside of 37.82% from the current price of $7.80.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Hold	Hold	Hold	Reduce
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$10.75	$18.75	$20.25	$105.00
Forecasted Upside	37.82% Upside	34.42% Upside	48.14% Upside	-1.96% Downside

Get Singular Genomics Systems Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OMIC and its competitors with MarketBeat's FREE daily newsletter.

Ad The Oxford Club

Man Who Called Nvidia at $1.10 Says Buy This Now...

In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.

Watch Alex's "Next Magnificent Seven" presentation now.

OMIC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

OMIC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Singular Genomics Systems Stock vs. The Competition

Type	Singular Genomics Systems	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	37.82% Upside	3,123.38% Upside	9.16% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
7/9/2024	The Goldman Sachs Group 2 of 5 stars	Lower Target	Neutral ➝ Neutral	$22.50 ➝ $6.50	-13.91%
3/20/2024	UBS Group 4 of 5 stars	Boost Target	Neutral ➝ Neutral	$12.00 ➝ $15.00	-0.06%
8/10/2022	Bank of America 4 of 5 stars	Downgrade	Buy ➝ Underperform	$90.00	-32.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:37 AM ET.

OMIC Forecast - Frequently Asked Questions

What is Singular Genomics Systems' forecast for 2024?: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Singular Genomics Systems is $10.75, with a high forecast of $15.00 and a low forecast of $6.50.
Should I buy or sell Singular Genomics Systems stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares.
Does Singular Genomics Systems's stock price have much downside?: According to analysts, Singular Genomics Systems's stock has a predicted downside of -4.69% based on their 12-month stock forecasts.
What analysts cover Singular Genomics Systems?: Singular Genomics Systems has been rated by research analysts at The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Singular Genomics Systems more than its competitors?: Analysts like Singular Genomics Systems less than other "medical" companies. The consensus rating for Singular Genomics Systems is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how OMIC compares to other companies.